Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer, March 2021

Free Subscription


Abstracts

Retrieve all available abstracts of the following 262 articles:
HTML format


 

Single Articles

  1. AKCAY A, Yagci AB, Celen S, Ozlulerden Y, et al
    VI-RADS score and tumor contact length in MRI: A potential method for the detection of muscle invasion in bladder cancer.
    Clin Imaging. 2021;77:25-36.
    PubMed    
    Abstract available

  2. HUANG H, Fan X, Qiao Y, Yang M, et al
    Knockdown of KNTC1 Inhibits the Proliferation, Migration and Tumorigenesis of Human Bladder Cancer Cells and Induces Apoptosis.
    Crit Rev Eukaryot Gene Expr. 2021;31:49-60.
    PubMed    
    Abstract available

  3. YILDIZ HA, Deger MD, Aslan G
    Prognostic Value of Preoperative Inflammation Markers in Non-Muscle Invasive Bladder Cancer.
    Int J Clin Pract. 2021 Feb 26:e14118. doi: 10.1111/ijcp.14118.
    PubMed    
    Abstract available

  4. TAO L, Mu X, Chen H, Jin D, et al
    FTO modifies the m6A level of MALAT and promotes bladder cancer progression.
    Clin Transl Med. 2021;11:e310.
    PubMed    
    Abstract available

  5. CAI EY, Garcia J, Liu Y, Vakar-Lopez F, et al
    A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture.
    Sci Rep. 2021;11:4609.
    PubMed    
    Abstract available

  6. XIU W, Luo J
    Correction to: CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling.
    BMC Immunol. 2021;22:18.
    PubMed    


  7. INGENWERTH M, Nyirady P, Hadaschik B, Szarvas T, et al
    The prognostic value of cytokeratin and extracellular collagen expression in urinary bladder cancer.
    Curr Mol Med. 2021 Feb 24. pii: CMM-EPUB-114544.
    PubMed    
    Abstract available

  8. CHEN LQ, Yi CL, Liu DC, Wang P, et al
    Hsa_circ_0041103 induces proliferation, migration and invasion in bladder cancer via the miR-107/FOXK1 axis.
    Eur Rev Med Pharmacol Sci. 2021;25:1282-1290.
    PubMed    
    Abstract available

  9. RUAN Q, Ding D, Wang B, He C, et al
    A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer.
    Cancer Biol Med. 2021;18:308-317.
    PubMed    
    Abstract available

  10. TADRIST A, Gondran-Tellier B, McManus R, Al-Balushi K, et al
    Primary Complete Transurethral Resection of Bladder Tumor using Photodynamic Diagnosis for High-risk Non-Muscle Invasive Bladder Cancer: Is a Restaging Photodynamic Transurethral Resection Really Necessary?
    J Endourol. 2021 Feb 25. doi: 10.1089/end.2020.1107.
    PubMed    
    Abstract available

  11. ZHANG D, Reyes RM, Osta E, Kari S, et al
    Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy.
    Cancer Med. 2021 Feb 24. doi: 10.1002/cam4.3739.
    PubMed    
    Abstract available

  12. ZHAO Y, Shi Z, Hao Z, Zhou J, et al
    Hypoxia-mediated down-regulation of miRNAs' biogenesis promotes tumor immune escape in bladder cancer.
    Clin Transl Oncol. 2021 Feb 24. pii: 10.1007/s12094-021-02569.
    PubMed    
    Abstract available

  13. CHOKSI A, Wang S, Phelan M, Mannuel H, et al
    Race as a predictor of pathologic response to neoadjuvant chemotherapy at time of cystectomy for bladder cancer.
    Can J Urol. 2021;28:10547-10555.
    PubMed    
    Abstract available

  14. ALKASSIS M, Kourie HR, Sarkis J, Nemr E, et al
    Predictive biomarkers in bladder cancer.
    Biomark Med. 2021;15:241-246.
    PubMed    


  15. RELIGIONI U, Czerw A, Deptala A
    Assessment of Pain, Acceptance of Illness, Adaptation to Life, and Strategies of Coping With the Disease, in Patients With Bladder Cancer.
    In Vivo. 2021;35:1157-1161.
    PubMed    
    Abstract available

  16. KAGEYAMA S, Maeda K, Kubota S, Yoshida T, et al
    Single Short Retention Instillation of Pirarubicin Prevents Intravesical Recurrence of Low-risk Non Muscle Invasive Bladder Cancer.
    In Vivo. 2021;35:1141-1145.
    PubMed    
    Abstract available

  17. NEMOTO Y, Kondo T, Ishihara H, Takagi T, et al
    The Controlling Nutritional Status CONUT Score in Patients With Advanced Bladder Cancer After Radical Cystectomy.
    In Vivo. 2021;35:999-1006.
    PubMed    
    Abstract available

  18. MINATO A, Noguchi H, Ohnishi R, Tomisaki I, et al
    Reduced Expression Level of GPX2 in T1 Bladder Cancer and its Role in Early-phase Invasion of Bladder Cancer.
    In Vivo. 2021;35:753-759.
    PubMed    
    Abstract available

  19. GE X, Lan ZK, Chen J, Zhu SY, et al
    Effectiveness of contrast-enhanced ultrasound for detecting the staging and grading of bladder cancer: a systematic review and meta-analysis.
    Med Ultrason. 2021;23:29-35.
    PubMed    
    Abstract available

  20. GUO Q, Ni P, Dai Y, Hu J, et al
    Long-Chain Noncoding RNA ADAMTS9-AS2 Regulates Proliferation, Migration, and Apoptosis in Bladder Cancer Cells Through Regulating miR-182-5p.
    J Interferon Cytokine Res. 2021;41:60-71.
    PubMed    
    Abstract available

  21. BOLAT D, Yarimoglu S, Aydin ME
    Monopolar versus bipolar transurethral resection of lateral wall-located bladder cancer under obturator nerve block: a single center prospective randomized study.
    Int Braz J Urol. 2021;47:584-593.
    PubMed    
    Abstract available

  22. GAO RZ, Wen R, Wen DY, Huang J, et al
    Radiomics Analysis Based on Ultrasound Images to Distinguish the Tumor Stage and Pathological Grade of Bladder Cancer.
    J Ultrasound Med. 2021 Feb 21. doi: 10.1002/jum.15659.
    PubMed    
    Abstract available

  23. SEKINO Y, Ishikawa H, Kimura T, Kojima T, et al
    Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART) - A study protocol for an open-label, phase II, multicenter study.
    Contemp Clin Trials Commun. 2021;21:100724.
    PubMed    
    Abstract available

  24. YANG C, Mou Z, Zhang Z, Wu S, et al
    Circular RNA RBPMS inhibits bladder cancer progression via miR-330-3p/RAI2 regulation.
    Mol Ther Nucleic Acids. 2021;23:872-886.
    PubMed    
    Abstract available

  25. GONG M, Song E, Huang G, Ni W, et al
    Enhanced Expression of CNTD2/CCNP Predicts Poor Prognosis in Bladder Cancer Based on the GSE13507.
    Front Genet. 2021;12:579900.
    PubMed    
    Abstract available

  26. SZABADOS B, Rodriguez-Vida A, Duran I, Crabb SJ, et al
    Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial.
    Eur Urol Oncol. 2021 Feb 18. pii: S2588-9311(20)30206.
    PubMed    
    Abstract available

  27. SLEVIN F, Henry AM
    Muscle-invasive Bladder Cancer in the Elderly Patient With a Focus on Hypofractionated Radiotherapy.
    Clin Oncol (R Coll Radiol). 2021 Feb 18. pii: S0936-6555(21)00045.
    PubMed    
    Abstract available

  28. TICONOSCO M, Assumma S, Iseppi A, Benedetti M, et al
    Expression of aquaporins 3 in low grade risk of recurrence primary bladder cancer.
    Urologia. 2021 Feb 21:391560321993588. doi: 10.1177/0391560321993588.
    PubMed    
    Abstract available

  29. LIU S, Chen X, Lin T
    Lymphatic metastasis of bladder cancer: Molecular mechanisms, diagnosis and targeted therapy.
    Cancer Lett. 2021;505:13-23.
    PubMed    
    Abstract available

  30. ZHENG D, Liu J, Wu G, Yang S, et al
    Comparison of open and intracorporeal modified ureterosigmoidostomy (Mainz II) after laparoscopic radical cystectomy with bladder cancer.
    World J Surg Oncol. 2021;19:57.
    PubMed    
    Abstract available

  31. WENG H, Yuan S, Huang Q, Zeng XT, et al
    STAT1 is a key gene in a gene regulatory network related to immune phenotypes in bladder cancer: An integrative analysis of multi-omics data.
    J Cell Mol Med. 2021 Feb 19. doi: 10.1111/jcmm.16395.
    PubMed    
    Abstract available

  32. AKABANE K, Uchida T, Matsuo S, Hirooka S, et al
    Hybrid operation for infectious thoracic and abdominal aortic aneurysms complicated with Bacillus Calmette-Guerin therapy for bladder cancer: A case report.
    Medicine (Baltimore). 2021;100:e24796.
    PubMed    
    Abstract available

  33. ROSELLEN J, Steffens J
    Unexplained Lower Abdominal Pain In Cystic Urinary Bladder Tumor.
    Dtsch Arztebl Int. 2020;117:782.
    PubMed    


  34. JUNG M, Jang I, Kim K, Moon KC, et al
    Non-Muscle-Invasive Bladder Carcinoma with Respect to Basal Versus Luminal Keratin Expression.
    Int J Mol Sci. 2020;21.
    PubMed    
    Abstract available

  35. NEUMANN NM, Haffner MC, Argani P, Kao CS, et al
    Histopathologic Characterization of Bladder Perivascular Epithelioid Cell Neoplasms (PEComa): A Series of 11 Cases With a Subset Having TFE3 Rearrangements.
    Am J Surg Pathol. 2021;45:169-177.
    PubMed    
    Abstract available

  36. SUNIL V N, John K, Nawahirsha S, Iyyadurai R, et al
    Micturition syncope: a rare presentation of bladder paraganglioma.
    BMJ Case Rep. 2020;13.
    PubMed    
    Abstract available

  37. ORSOLIC N, Odeh D, Jembrek MJ, Knezevic J, et al
    Interactions between Cisplatin and Quercetin at Physiological and Hyperthermic Conditions on Cancer Cells In Vitro and In Vivo.
    Molecules. 2020;25.
    PubMed    
    Abstract available

  38. STOKKEL LE, Mertens LS, van Rhijn BWG
    ASO Author Reflections: How to Detect Peritoneal Metastases of Urachal Carcinoma? The Value of Diagnostic Laparoscopy and Abdominal Cytology in Staging This Rare Malignancy.
    Ann Surg Oncol. 2020;27:2476-2477.
    PubMed    


  39. DANKNER R, Roth J
    More recent, better designed studies have weakened links between antidiabetes medications and cancer risk.
    Diabet Med. 2020;37:194-202.
    PubMed    
    Abstract available

  40. KARDOUST PARIZI M, Enikeev D, Glybochko PV, Seebacher V, et al
    Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis.
    World J Urol. 2020;38:1437-1449.
    PubMed    
    Abstract available

  41. TSCHIRDEWAHN S, Harke NN, Hirner L, Stagge E, et al
    Narrow-band imaging assisted cystoscopy in the follow-up of patients with transitional cell carcinoma of the bladder: a randomized study in comparison with white light cystoscopy.
    World J Urol. 2020;38:1509-1515.
    PubMed    
    Abstract available

  42. DEL GIUDICE F, Busetto GM, Gross MS, Maggi M, et al
    Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis.
    J Cancer Res Clin Oncol. 2021 Mar 6. pii: 10.1007/s00432-021-03571.
    PubMed    
    Abstract available

  43. RAPHAEL MJ, Griffiths R, Peng Y, Gupta S, et al
    Mental Health Resource Use Among Patients Undergoing Curative Intent Treatment for Bladder Cancer.
    J Natl Cancer Inst. 2021 Mar 1. pii: 6154859. doi: 10.1093.
    PubMed    
    Abstract available

  44. IKEDA S, Sobue T, Kitamura T, Ishihara J, et al
    Dietary Acrylamide Intake and the Risks of Renal Cell, Prostate, and Bladder Cancers: A Japan Public Health Center-Based Prospective Study.
    Nutrients. 2021;13.
    PubMed    
    Abstract available

  45. TSE RT, Zhao H, Wong CY, Cheng CK, et al
    Urinary Cell-Free DNA in Bladder Cancer Detection.
    Diagnostics (Basel). 2021;11.
    PubMed    
    Abstract available

  46. PICHLER R, Lindner AK, Schafer G, Tulchiner G, et al
    Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study.
    J Clin Med. 2021;10.
    PubMed    
    Abstract available

  47. CRETA M, Celentano G, Napolitano L, La Rocca R, et al
    Inhibition of Androgen Signalling Improves the Outcomes of Therapies for Bladder Cancer: Results from a Systematic Review of Preclinical and Clinical Evidence and Meta-Analysis of Clinical Studies.
    Diagnostics (Basel). 2021;11.
    PubMed    
    Abstract available

  48. HOFFMANN MJ, Meneceur S, Hommel K, Schulz WA, et al
    Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells.
    Genes (Basel). 2021;12.
    PubMed    
    Abstract available

  49. KUFUKIHARA R, Kikuchi E, Ogihara K, Shigeta K, et al
    Role of Previous Malignancy History in Clinical Outcomes in Patients with Initially Diagnosed Non-Muscle Invasive Bladder Cancer.
    Ann Surg Oncol. 2021 Mar 5. pii: 10.1245/s10434-021-09750.
    PubMed    
    Abstract available

  50. MENG J, Lu X, Zhou Y, Zhang M, et al
    Tumor immune microenvironment-based classifications of bladder cancer for enhancing the response rate of immunotherapy.
    Mol Ther Oncolytics. 2021;20:410-421.
    PubMed    
    Abstract available

  51. CAI YX, Yang X, Lin S, Xu YW, et al
    Low-Coverage Sequencing of Urine Sediment DNA for Detection of Copy Number Aberrations in Bladder Cancer.
    Cancer Manag Res. 2021;13:1943-1953.
    PubMed    
    Abstract available

  52. XU H, Ju L, Xiong Y, Yu M, et al
    E3 ubiquitin ligase RNF126 affects bladder cancer progression through regulation of PTEN stability.
    Cell Death Dis. 2021;12:239.
    PubMed    
    Abstract available

  53. HUANG D, Zhou S, Yu Z, Chen J, et al
    Lung protective ventilation strategy to reduce postoperative pulmonary complications (PPCs) in patients undergoing robot-assisted laparoscopic radical cystectomy for bladder cancer: A randomized double blinded clinical trial.
    J Clin Anesth. 2021;71:110156.
    PubMed    
    Abstract available

  54. CHEN C, Zheng H, Luo Y, Kong Y, et al
    SUMOylation promotes extracellular vesicle-mediated transmission of lncRNA ELNAT1 and lymph node metastasis in bladder cancer.
    J Clin Invest. 2021 Mar 4. pii: 146431. doi: 10.1172/JCI146431.
    PubMed    
    Abstract available

  55. WULFF-BURCHFIELD EM, Potts M, Glavin K, Mirza M, et al
    A qualitative evaluation of a nurse-led pre-operative stoma education program for bladder cancer patients.
    Support Care Cancer. 2021 Mar 4. pii: 10.1007/s00520-021-06093.
    PubMed    
    Abstract available

  56. DING T, Yang B, Yang D, Zhang P, et al
    Screening of MicroRNA Biomarkers Related to the Progression of Bladder Cancer.
    Cancer Biother Radiopharm. 2021 Mar 3. doi: 10.1089/cbr.2020.4217.
    PubMed    
    Abstract available

  57. JIANG DM, Chung P, Kulkarni GS, James ND, et al
    Lack of Evidence Does Not Equal Lack of Benefit: Neoadjuvant Chemotherapy and Trimodality Therapy in Selected Patients with Muscle-Invasive Bladder Cancer : In response to: Dirk Bohmer and Arne Grun. Lacking Evidence to Recommend Neoadjuvant Chemother
    Curr Oncol Rep. 2021;23:36.
    PubMed    


  58. SHLYAPNIKOV YM, Malakhova EA, Vinarov AZ, Zamyatnin AA Jr, et al
    Can new immunoassay techniques improve bladder cancer diagnostics With protein biomarkers?
    Front Mol Biosci. 2021;7:620687.
    PubMed    
    Abstract available

  59. XU Z, Gujar H, Fu G, Ahmadi H, et al
    A Novel DNA Methylation Signature as an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer.
    Front Oncol. 2021;11:614927.
    PubMed    
    Abstract available

  60. NASSIF EF, Thibault C, Oudard S, Galon J, et al
    Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer.
    Oncoimmunology. 2021;10:1888488.
    PubMed    
    Abstract available

  61. TIAN Y, Guan Y, Su Y, Yang T, et al
    TRPM2-AS Promotes Bladder Cancer by Targeting miR-22-3p and Regulating GINS2 mRNA Expression.
    Onco Targets Ther. 2021;14:1219-1237.
    PubMed    
    Abstract available

  62. WU S, Yang J, Xu H, Wang X, et al
    Circular RNA circGLIS3 promotes bladder cancer proliferation via the miR-1273f/SKP1/Cyclin D1 axis.
    Cell Biol Toxicol. 2021 Mar 3. pii: 10.1007/s10565-021-09591.
    PubMed    
    Abstract available

  63. ANDINO JJ, Sessine M, Singhal U, Reichert ZR, et al
    Understanding the Barriers to Neoadjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer: A Quality Improvement Initiative.
    Urol Pract. 2021;8:217-225.
    PubMed    
    Abstract available

  64. JI N, Mukherjee N, Reyes RM, Gelfond J, et al
    Rapamycin enhances BCG-specific gammadelta T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study.
    J Immunother Cancer. 2021;9.
    PubMed    
    Abstract available

  65. LORENCIN I, Baressi Segota S, Andelic N, Mrzljak V, et al
    On Urinary Bladder Cancer Diagnosis: Utilization of Deep Convolutional Generative Adversarial Networks for Data Augmentation.
    Biology (Basel). 2021;10.
    PubMed    
    Abstract available

  66. JIANG G, Teramoto Y, Goto T, Mizushima T, et al
    Identification of BXDC2 as a Key Downstream Effector of the Androgen Receptor in Modulating Cisplatin Sensitivity in Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  67. SZABO Z, Dezso B, Fodor K, Szegedi K, et al
    Expression of Luteinizing Hormone-Releasing Hormone (LHRH) and Type-I LHRH Receptor in Transitional Cell Carcinoma Type of Human Bladder Cancer.
    Molecules. 2021;26.
    PubMed    
    Abstract available

  68. GANIEF T, Calder B, Blackburn JM
    Protocols for Preparation and Mass Spectrometry Analysis of Clinical Urine Samples to Identify Candidate Biomarkers of Schistosoma-Associated Bladder Cancer.
    Methods Mol Biol. 2021;2292:143-150.
    PubMed    
    Abstract available

  69. CASADIO V, Bravaccini S
    Telomerase Activity Analysis In Urine Sediment for Bladder Cancer.
    Methods Mol Biol. 2021;2292:133-141.
    PubMed    
    Abstract available

  70. COSTANTINI M, Gallo G, Attolini G
    Urinary Biomarkers In Bladder Cancer.
    Methods Mol Biol. 2021;2292:121-131.
    PubMed    
    Abstract available

  71. NAKANO M, Shinagawa T, Eitaki Y, Omae K, et al
    Risk of bladder cancer in male Japanese workers exposed to ortho-toluidine and other aromatic amines.
    Int Arch Occup Environ Health. 2021 Mar 2. pii: 10.1007/s00420-021-01658.
    PubMed    
    Abstract available

  72. POLANCO-PUJOL L, Cano-Velasco J, Moralejo-Garate M, Bataller-Monfort V, et al
    [Penile metastasis from urothelial carcinoma: Review of literature.]
    Arch Esp Urol. 2021;74:208-214.
    PubMed    
    Abstract available

  73. GARCZYK S, Bischoff F, Schneider U, Golz R, et al
    Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
    Virchows Arch. 2021 Mar 1. pii: 10.1007/s00428-021-03054.
    PubMed    
    Abstract available

  74. DENG J, Peng M, Zhou S, Xiao D, et al
    Metformin targets Clusterin to control lipogenesis and inhibit the growth of bladder cancer cells through SREBP-1c/FASN axis.
    Signal Transduct Target Ther. 2021;6:98.
    PubMed    


  75. SANVILLE BC, Kuhn BT
    A 56-Year-Old Male With Weight Loss, Night Sweats, Dyspnea, and Bladder Cancer.
    J Investig Med High Impact Case Rep. 2021;9:2324709621997246.
    PubMed    
    Abstract available

  76. CHEN D, Xie S, Wu Y, Cui Y, et al
    Reduction of Bladder Cancer Chemosensitivity Induced by the Effect of HOXA-AS3 as a ceRNA for miR-455-5p That Upregulates Notch1.
    Front Oncol. 2021;10:572672.
    PubMed    
    Abstract available

  77. LI J, Park A, Fulmer BR, Garg T, et al
    Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria.
    Urol Case Rep. 2021;36:101579.
    PubMed    
    Abstract available

  78. FELDMAN AS, Kulkarni GS, Bivalacqua TJ, Black PC, et al
    Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer.
    Urol Oncol. 2021 Feb 25. pii: S1078-1439(21)00012.
    PubMed    
    Abstract available

  79. TRIPATHI A, Khaki AR, Grivas P
    Perioperative Immunotherapy in Muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2021 Feb 25. pii: S2588-9311(21)00028.
    PubMed    
    Abstract available

  80. LENIS AT, Fero KE, Ojeaburu L, Lec PM, et al
    The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy.
    Urol Oncol. 2021 Feb 24. pii: S1078-1439(21)00016.
    PubMed    
    Abstract available

  81. ODERDA M, Calleris G, Falcone M, Fasolis G, et al
    How uro-oncology has been affected by COVID-19 emergency? Data from Piedmont/Valle d'Aosta Oncological Network, Italy.
    Urologia. 2021;88:3-8.
    PubMed    
    Abstract available

  82. ARUNACHALAM P, Sen S, Balaji D, Sam CJ, et al
    Paediatric bladder neurofibroma on bilateral ureterostomy: rare case report-strategic management.
    BMJ Case Rep. 2021;14.
    PubMed    
    Abstract available

  83. YANG HY, Wu CY, Chen JJ, Lee TH, et al
    Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review.
    Int J Mol Sci. 2020;21.
    PubMed    
    Abstract available

  84. ROVIELLO G, Catalano M, Nobili S, Santi R, et al
    Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
    Int J Mol Sci. 2020;21.
    PubMed    
    Abstract available

  85. SATHUA K, Srivastava S, Flora SJS
    MiADMSA ameliorate arsenic induced urinary bladder carcinogenesis in vivo and in vitro.
    Biomed Pharmacother. 2020;128:110257.
    PubMed    
    Abstract available

  86. AHMAD W, Gill SM, Hassan A
    A rare presentation of primary synchronous renal tract tumours on (18F)- fluorodeoxyglucose positron emission tomography- computed tomography.
    J Pak Med Assoc. 2020;70:942-943.
    PubMed    
    Abstract available

  87. SUN J, Ma X, Shen H, Liu B, et al
    Effects of fluorescent light cystoscopy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Photodiagnosis Photodyn Ther. 2021 Mar 9:102248.
    PubMed    
    Abstract available

  88. LV Z, Pang C, Wang J, Xia H, et al
    Identification of a prognostic signature based on immune-related genes in bladder cancer.
    Genomics. 2021 Mar 9. pii: S0888-7543(21)00104.
    PubMed    
    Abstract available

  89. BENIDIR T, Herrera-Caceres J, Wallis C, Lajkosz K, et al
    Population-based analysis of perioperative chemotherapy use, interventions requiring hospitalization and atheroembolic events among patients with non-metastatic muscle-invasive bladder cancer.
    Cancer Med. 2021 Mar 12. doi: 10.1002/cam4.3805.
    PubMed    
    Abstract available

  90. ZHOU C, Wang G, Jing W, Tan X, et al
    Anticancer Properties and Mechanisms of Singly-Protonated Dehydronorcantharidin Silver Coordination Polymer in a Bladder Cancer Model.
    Front Pharmacol. 2021;12:618668.
    PubMed    
    Abstract available

  91. ROUANNE M, Gaillard F, Meunier ME, Soorojebally Y, et al
    Author Correction: Measured glomerular filtration rate (GFR) significantly and rapidly decreases after radical cystectomy for bladder cancer.
    Sci Rep. 2021;11:6155.
    PubMed    


  92. RUAN JL, Browning RJ, Yildiz YO, Bau L, et al
    Evaluation of Loading Strategies to Improve Tumor Uptake of Gemcitabine in a Murine Orthotopic Bladder Cancer Model Using Ultrasound and Microbubbles.
    Ultrasound Med Biol. 2021 Mar 8. pii: S0301-5629(21)00058.
    PubMed    
    Abstract available

  93. PARMAR A, Richardson M, Coyte PC, Cheng S, et al
    A Cost-Utility Analysis of Atezolizumab in the Second-Line Treatment of Patients with Metastatic Bladder Cancer.
    Curr Oncol. 2020;27:386-394.
    PubMed    
    Abstract available

  94. AL-SARAIREH YM, Alshammari FOFO, Youssef AMM, Al-Sarayreh S, et al
    Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers.
    Sci Rep. 2021;11:5581.
    PubMed    
    Abstract available

  95. KALUZINSKA Z, Kolat D, Kosla K, Orzechowska M, et al
    In vitro and in silico assessment of the effect of WWOX expression on invasiveness pathways associated with AP-2 transcription factors in bladder cancer.
    BMC Urol. 2021;21:36.
    PubMed    
    Abstract available

  96. ZHOU X, Liu S, Yao S, Huo Z, et al
    Clinical features and management experience in patients with metastatic spinal bladder cancer: a single-institution 10-year retrospective study.
    Ann Palliat Med. 2021 Mar 9. pii: apm-20-1980. doi: 10.21037/apm-20-1980.
    PubMed    
    Abstract available

  97. DU S, Sui Y, Ren W, Zhou J, et al
    PYCR1 promotes bladder cancer by affecting the Akt/Wnt/beta-catenin signaling.
    J Bioenerg Biomembr. 2021 Mar 10. pii: 10.1007/s10863-021-09887.
    PubMed    
    Abstract available

  98. SHENG H, Zhang G, Huang Y, Sun L, et al
    A 5-lncRNA Signature Associated with Smoking Predicts the Overall Survival of Patients with Muscle-Invasive Bladder Cancer.
    Dis Markers. 2021;2021:8839747.
    PubMed    
    Abstract available

  99. MIKHALEVA LM, Pechnikova VV, Pshikhachev AM, Rogov KA, et al
    Bladder Cancer: Update on Risk Factors, Molecular and Ultrastructural Patterns.
    Curr Med Chem. 2021 Mar 8. pii: CMC-EPUB-114794.
    PubMed    
    Abstract available

  100. ZHANG HH, Li C, Ren JW, Liu L, et al
    OTUB1 facilitates bladder cancer progression by stabilizing ATF6 in response to ER stress.
    Cancer Sci. 2021 Mar 9. doi: 10.1111/cas.14876.
    PubMed    
    Abstract available

  101. SCHULZ GB, Elezkurtaj S, Bording T, Schmidt EM, et al
    Therapeutic and prognostic implications of NOTCH and MAPK signaling in bladder cancer.
    Cancer Sci. 2021 Mar 8. doi: 10.1111/cas.14878.
    PubMed    
    Abstract available

  102. YU EY, Wesselius A, Mehrkanoon S, Goosens M, et al
    Vegetable intake and the risk of bladder cancer in the BLadder Cancer Epidemiology and Nutritional Determinants (BLEND) international study.
    BMC Med. 2021;19:56.
    PubMed    
    Abstract available

  103. MAO X, Nanzhang, Xiao J, Wu H, et al
    Hypoxia-Induced Autophagy Enhances Cisplatin Resistance in Human Bladder Cancer Cells by Targeting Hypoxia-Inducible Factor-1alpha.
    J Immunol Res. 2021;2021:8887437.
    PubMed    
    Abstract available

  104. WANG G, Dai Y, Li K, Cheng M, et al
    Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis.
    Front Cell Dev Biol. 2021;9:627706.
    PubMed    
    Abstract available

  105. NIIMI F, Danno T, Iwata S, Honda S, et al
    Submucosal urothelial bladder cancer: A case report.
    Mol Clin Oncol. 2021;14:77.
    PubMed    
    Abstract available

  106. MASIERO M, Busacchio D, Guiddi P, Arnaboldi P, et al
    Quality of life and psycho-emotional wellbeing in bladder cancer patients and their caregivers: a comparative analysis between urostomy versus ileal orthotopic neobladder.
    Ecancermedicalscience. 2021;15:1163.
    PubMed    
    Abstract available

  107. BOBJER J, Hagberg O, Aljabery F, Gardmark T, et al
    A population-based study on the effect of a routine second-look resection on survival in primary stage T1 bladder cancer.
    Scand J Urol. 2021 Mar 6:1-8. doi: 10.1080/21681805.2021.1892179.
    PubMed    
    Abstract available

  108. HUGAR LA, Yabes JG, Filippou P, Wulff-Burchfield EM, et al
    High-intensity end-of-life care among Medicare beneficiaries with bladder cancer.
    Urol Oncol. 2021 Mar 3. pii: S1078-1439(21)00068.
    PubMed    
    Abstract available

  109. WISSING MD, O'Flaherty A, Dragomir A, Tanguay S, et al
    The Use of 5-Alpha Reductase Inhibitors and Alpha-1 Blockers Does Not Improve Clinical Outcome in Male Patients Undergoing Radical Cystectomy for Bladder Cancer in Quebec, Canada.
    Clin Genitourin Cancer. 2021 Feb 6. pii: S1558-7673(21)00030.
    PubMed    
    Abstract available

  110. NEO SH, Lee LS
    A Large Abdominal Mass.
    N Engl J Med. 2021;384:e24.
    PubMed    


  111. GALSKY MD, Grande E
    PD-1 inhibitors for urothelial cancer: combination or sequential therapy? - Authors' reply.
    Lancet. 2021;396:1977-1978.
    PubMed    


  112. IIZUKA K, Shoji K, Fujiyuki T, Moritoh K, et al
    Antitumor activity of an oncolytic measles virus against canine urinary bladder transitional cell carcinoma cells.
    Res Vet Sci. 2020;133:313-317.
    PubMed    
    Abstract available

  113. WU K, Liang J, Lu Y
    Risk factors and survival outcomes of metachronous contralateral upper tract urothelial carcinoma.
    Sci Rep. 2020;10:16600.
    PubMed    
    Abstract available

  114. SAHAN A, Gerin F, Garayev A, Bozkurtlar E, et al
    The impact of tumor invasion to muscularis mucosaevascular plexus on patient outcome in pT1 bladder urothelial carcinoma.
    Arch Ital Urol Androl. 2020;92.
    PubMed    
    Abstract available

  115. CORONGIU E, Grande P, Liberati E, Iacovelli R, et al
    Clear Cell carcinoma of the urinary bladder, A case report: Surgical and oncological management.
    Arch Ital Urol Androl. 2020;92.
    PubMed    
    Abstract available

  116. OLIVIERI V, Fortunati V, Bellei L, Massarelli M, et al
    Primary small-cell neuroendocrine carcinoma of the bladder: Case report and literature review.
    Arch Ital Urol Androl. 2020;92.
    PubMed    
    Abstract available

  117. CHIANCONE F, Carrino M, Fedelini M, Fabiano M, et al
    The role of Protopine associated with Nuciferine in controlling adverse events during hyperthermic intravesical chemotherapy instillations. A nutraceutical approach to control adverse event during intravesical instillations.
    Arch Ital Urol Androl. 2020;92.
    PubMed    
    Abstract available

  118. D'ANGELO A, Bagby S, Galli IC, Bortoletti C, et al
    Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
    Expert Rev Clin Pharmacol. 2020;13:1139-1146.
    PubMed    
    Abstract available

  119. PODARALA V, Prasanna Lakshmi M, Venkata SKR, Devalam RP, et al
    Efficacy of BCG vaccine and Mitomycin C for the treatment of ocular squamous cell carcinoma in bovines.
    Res Vet Sci. 2020;133:48-52.
    PubMed    
    Abstract available

  120. COLL PP, Korc-Grodzicki B, Ristau BT, Shahrokni A, et al
    Cancer Prevention and Screening for Older Adults: Part 1. Lung, Colorectal, Bladder, and Kidney Cancer.
    J Am Geriatr Soc. 2020;68:2399-2406.
    PubMed    
    Abstract available

  121. FEDELI U, Porreca A, Colicchia M, Schievano E, et al
    Intravescical instillation of Calmette-Guerin bacillus and COVID-19 risk.
    Hum Vaccin Immunother. 2021;17:416-417.
    PubMed    
    Abstract available

  122. KHAN J, Kamal MS, D'Arcy FT, Dowling C, et al
    Biopsy at flexible cystoscopy: is it worthwhile?
    Ir J Med Sci. 2021;190:437-439.
    PubMed    
    Abstract available

  123. FENG D, Tang Y, Yang Y, Han P, et al
    Intracorporeal versus extracorporeal urinary diversion after robotic-assisted radical cystectomy: evidence from a systematic review and pooled analysis of observational studies.
    Minerva Urol Nefrol. 2020;72:519-530.
    PubMed    
    Abstract available

  124. XU S, Zuo L
    Association between methylenetetrahydrofolate reductase gene rs1801131 A/C polymorphism and urinary tumors' susceptibility.
    Hereditas. 2020;157:16.
    PubMed    
    Abstract available

  125. STOKKEL LE, Mehta AM, Behrendt MA, de Jong J, et al
    Diagnostic Laparoscopy and Abdominal Cytology Reliably Detect Peritoneal Metastases in Patients with Urachal Adenocarcinoma.
    Ann Surg Oncol. 2020;27:2468-2475.
    PubMed    
    Abstract available

  126. WANG H, Chong T, Tang XY, Zheng WB, et al
    Transurethral resection in women with symptomatic keratinizing squamous metaplasia of urinary bladder: A retrospective study of 92 cases.
    Low Urin Tract Symptoms. 2020;12:137-142.
    PubMed    
    Abstract available

  127. PASPULATI A, Gupta A, Hill PA, Morgan MA, et al
    The utility of retrograde pyelography to follow up incompletely opacified ureters on CT urography.
    Abdom Radiol (NY). 2020;45:807-811.
    PubMed    
    Abstract available

  128. SUN YJ, Li AW, Zhang YC, Dai JH, et al
    Evaluation of Urine NDRG1 as Noninvasive Biomarker for Bladder Cancer Diagnosis.
    Clin Lab. 2021;67.
    PubMed    
    Abstract available

  129. SANGUEDOLCE F, Calo B, Mancini V, Zanelli M, et al
    Non-Muscle Invasive Bladder Cancer with Variant Histology: Biological Features and Clinical Implications.
    Oncology. 2021 Mar 18:1-14. doi: 10.1159/000514759.
    PubMed    
    Abstract available

  130. MENDES F, Pereira E, Martins D, Tavares-Silva E, et al
    Oxidative stress in bladder cancer: an ally or an enemy?
    Mol Biol Rep. 2021 Mar 17. pii: 10.1007/s11033-021-06266.
    PubMed    
    Abstract available

  131. ZHANG H, Song J, Dong J, Liu Z, et al
    Tumor Microenvironment Analysis Identified Subtypes Associated With the Prognosis and the Tumor Response to Immunotherapy in Bladder Cancer.
    Front Genet. 2021;12:551605.
    PubMed    
    Abstract available


  132. MiR-126 Regulates Proliferation and Invasion in the Bladder Cancer BLS Cell Line by Targeting the PIK3R2-Mediated PI3K/Akt Signaling Pathway [Retraction].
    Onco Targets Ther. 2021;14:1859.
    PubMed    
    Abstract available

  133. CARRASCO R, Izquierdo L, van der Heijden AG, Lozano JJ, et al
    Differential gene expression profile between progressive and de novo muscle invasive bladder cancer and its prognostic implication.
    Sci Rep. 2021;11:6132.
    PubMed    
    Abstract available

  134. ZENG F, Luo L, Li D, Guo J, et al
    KPNA2 interaction with CBX8 contributes to the development and progression of bladder cancer by mediating the PRDM1/c-FOS pathway.
    J Transl Med. 2021;19:112.
    PubMed    
    Abstract available

  135. YANG H, Qu H, Huang H, Mu Z, et al
    Exosomes-mediated transfer of long noncoding RNA LINC01133 represses bladder cancer progression via regulating Wnt signaling pathway.
    Cell Biol Int. 2021 Mar 16. doi: 10.1002/cbin.11590.
    PubMed    
    Abstract available

  136. HAN C, Chen S, Ma H, Wen X, et al
    RPN2 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and Metastasis via the PI3K-Akt Pathway.
    Onco Targets Ther. 2021;14:1643-1657.
    PubMed    
    Abstract available

  137. WILKINS A, Ost P, Sundahl N
    Is There a Benefit of Combining Immunotherapy and Radiotherapy in Bladder Cancer?
    Clin Oncol (R Coll Radiol). 2021 Mar 13. pii: S0936-6555(21)00085.
    PubMed    
    Abstract available

  138. DING Z, Ying W, He Y, Chen X, et al
    lncRNA-UCA1 in the diagnosis of bladder cancer: A meta-analysis.
    Medicine (Baltimore). 2021;100:e24805.
    PubMed    
    Abstract available

  139. SZCZESNY W, Szylberg L, Slupski M, Marszalek A, et al
    An unusual case of a tuberculous granuloma of the liver presenting thirteen years after intravesical BCG - therapy for bladder cancer.
    Pol Przegl Chir. 2020;93:1-5.
    PubMed    
    Abstract available

  140. FU D, Liu B, Jiang H, Li Z, et al
    Bone marrow mesenchymal stem cells-derived exosomal microRNA-19b-1-5p reduces proliferation and raises apoptosis of bladder cancer cells via targeting ABL2.
    Genomics. 2021 Mar 12. pii: S0888-7543(21)00103.
    PubMed    
    Abstract available

  141. TOMIYAMA E, Matsuzaki K, Fujita K, Shiromizu T, et al
    Proteomic analysis of urinary and tissue-exudative extracellular vesicles to discover novel bladder cancer biomarkers.
    Cancer Sci. 2021 Mar 15. doi: 10.1111/cas.14881.
    PubMed    
    Abstract available

  142. LUO G, Zhang Y, Wu Z, Zhang L, et al
    Exosomal LINC00355 derived from cancer-associated fibroblasts promotes bladder cancer cell resistance to cisplatin by regulating miR-34b-5p/ABCB1 axis.
    Acta Biochim Biophys Sin (Shanghai). 2021 Mar 15. pii: 6171055.
    PubMed    
    Abstract available

  143. OCHI A, Harada S, Fukuokaya W, Honma K, et al
    Bladder cancer invasion along a tension-free vaginal mesh.
    IJU Case Rep. 2021;4:104-107.
    PubMed    
    Abstract available

  144. HIJAB A, Tocco B, Hanson I, Meijer H, et al
    MR-Guided Adaptive Radiotherapy for Bladder Cancer.
    Front Oncol. 2021;11:637591.
    PubMed    
    Abstract available

  145. KOLAT D, Kaluzinska Z, Pluciennik E
    Fragile Gene WWOX Guides TFAP2A/TFAP2C-Dependent Actions Against Tumor Progression in Grade II Bladder Cancer.
    Front Oncol. 2021;11:621060.
    PubMed    
    Abstract available

  146. XU Y, Zhang P, Tan Y, Jia Z, et al
    A potential panel of five mRNAs in urinary extracellular vesicles for the detection of bladder cancer.
    Transl Androl Urol. 2021;10:809-820.
    PubMed    
    Abstract available

  147. FERRO M, Di Mauro M, Cimino S, Morgia G, et al
    Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer.
    Transl Androl Urol. 2021;10:626-635.
    PubMed    
    Abstract available

  148. SI L, Yang X, Yan X, Wang Y, et al
    Erratum: Isoliquiritigenin induces apoptosis of human bladder cancer T24 cells via a cyclin-dependent kinase-independent mechanism.
    Oncol Lett. 2021;21:268.
    PubMed    
    Abstract available

  149. DI MAIDA F, Scalici Gesolfo C, Tellini R, Mari A, et al
    Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy for non-muscle invasive bladder cancer.
    Ther Adv Urol. 2021;13:1756287221995683.
    PubMed    
    Abstract available

  150. AYDIN AM, Bunch BL, Beatty M, Hajiran A, et al
    The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications.
    Front Immunol. 2021;12:628063.
    PubMed    
    Abstract available

  151. RUAN JL, Browning RJ, Yildiz YO, Gray M, et al
    Ultrasound-Mediated Gemcitabine Delivery Reduces the Normal-Tissue Toxicity of Chemoradiation Therapy in a Muscle-Invasive Bladder Cancer Model.
    Int J Radiat Oncol Biol Phys. 2021;109:1472-1482.
    PubMed    
    Abstract available

  152. D'ANDREA D, Soria F, Grotenhuis AJ, Cha EK, et al
    Association of patients' sex with treatment outcomes after intravesical bacillus Calmette-Guerin immunotherapy for T1G3/HG bladder cancer.
    World J Urol. 2021 Mar 13. pii: 10.1007/s00345-021-03653.
    PubMed    
    Abstract available

  153. BRYAN RT, Arnold R, Khanim FL, Shepherd DE, et al
    Establishing the Bladder Cancer Research Centre at the University of Birmingham.
    Nat Rev Urol. 2021 Mar 12. pii: 10.1038/s41585-021-00448.
    PubMed    


  154. KRENTEL F, Singer F, Rosano-Gonzalez ML, Gibb EA, et al
    A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer.
    Sci Rep. 2021;11:5849.
    PubMed    
    Abstract available

  155. TABER A, Park Y, Lelo A, Prip F, et al
    STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer.
    Urol Oncol. 2021 Mar 9. pii: S1078-1439(21)00069.
    PubMed    
    Abstract available

  156. POLOM W, Cytawa W, Polom A, Szurowska E, et al
    Radionuclide-guided sentinel lymph node mapping in urachal cancer.
    Adv Clin Exp Med. 2021;30:203-210.
    PubMed    
    Abstract available

  157. SHIGETA K, Matsumoto K, Ogihara K, Murakami T, et al
    The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma.
    Cancer Sci. 2021;112:1084-1094.
    PubMed    
    Abstract available

  158. LIU Y, Xu H, Wu B, Liu S, et al
    Small cell carcinoma of the bladder with coexisting prostate adenocarcinoma: two cases report and literature review.
    BMC Urol. 2020;20:134.
    PubMed    
    Abstract available

  159. NOMURA S, Suzuki Y, Akatsuka J, Endo Y, et al
    Expression of epithelial-Mesenchymal transition related markers in Plasmacytoid Urothelial carcinoma of the urinary bladder.
    BMC Urol. 2020;20:72.
    PubMed    
    Abstract available

  160. LATTANZI M, Rosenberg JE
    The emerging role of antibody-drug conjugates in urothelial carcinoma.
    Expert Rev Anticancer Ther. 2020;20:551-561.
    PubMed    
    Abstract available

  161. TORRES N, Regge MV, Secchiari F, Friedrich AD, et al
    Restoration of antitumor immunity through anti-MICA antibodies elicited with a chimeric protein.
    J Immunother Cancer. 2020;8.
    PubMed    
    Abstract available

  162. NORMANN CO, Opheim R, Andreassen BK, Bernklev T, et al
    Health-related quality-of-life after radical cystectomy among Norwegian men and women compared to the general population.
    Scand J Urol. 2020;54:181-187.
    PubMed    
    Abstract available

  163. KAFFASH NAYERI R, Sadri M, Shahrokh H, Abolhasani M, et al
    Small Cell Carcinoma of Bladder; Still A Diagnostic and Therapeutic Challenge: Seven Years of Experience and Follow-up in A Referral Center.
    Urol J. 2020;17:363-369.
    PubMed    
    Abstract available

  164. AL-SHARAKY DR, Kandil MAE, Aiad HAS, El-Hosary EM, et al
    ROC-1, P21 and CAIX as markers of tumor aggressiveness in bladder carcinoma in Egyptian patients.
    Diagn Pathol. 2020;15:33.
    PubMed    
    Abstract available

  165. VOSKUILEN CS, Bosschieter J, Nieuwenhuijzen JA, van Rhijn BWG, et al
    Authors' response to Letter to the Editor "Don't forget Arnhem".
    Radiother Oncol. 2020;147:237.
    PubMed    


  166. VAN DER STEEN-BANASIK EM, Oosterveld BJ, Smits GA
    Don't forget Arnhem!
    Radiother Oncol. 2020;147:236.
    PubMed    


  167. WANG S, Zhang A, Huang S, Ma Y, et al
    Non Functioning Paraganglioma in the Urinary Bladder: a Case Report.
    Urol J. 2020;17:426-428.
    PubMed    
    Abstract available

  168. ZHANG C, Li Z, Hu J, Qi F, et al
    Identification of five long noncoding RNAs signature and risk score for prognosis of bladder urothelial carcinoma.
    J Cell Biochem. 2020;121:856-866.
    PubMed    
    Abstract available

  169. CANCEL-TASSIN G, Roupret M, Pinar U, Gaffory C, et al
    Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up.
    World J Urol. 2021 Mar 26. pii: 10.1007/s00345-021-03629.
    PubMed    
    Abstract available

  170. SEO WI, Lee CH, Jung SJ, Lee DS, et al
    Expression of VISTA on tumor-infiltrating immune cells correlated with short intravesical recurrence in non-muscle-invasive bladder cancer.
    Cancer Immunol Immunother. 2021 Mar 26. pii: 10.1007/s00262-021-02906.
    PubMed    
    Abstract available

  171. ZENG J, Xu H, Huang C, Sun Y, et al
    CD46 splice variant enhances translation of specific mRNAs linked to an aggressive tumor cell phenotype in bladder cancer.
    Mol Ther Nucleic Acids. 2021;24:140-153.
    PubMed    
    Abstract available

  172. TURKER P, Wernroth ML, Malmstrom PU, Segersten U, et al
    Combination of biomarkers for neoadjuvant systemic chemotherapy before cystectomy in patients with urinary bladder cancer.
    Transl Res. 2021 Mar 22. pii: S1931-5244(21)00076.
    PubMed    
    Abstract available

  173. HAFEEZ S, Lewis R, Hall E, Huddart R, et al
    Advancing Radiotherapy for Bladder Cancer: Randomised Phase II Trial of Adaptive Image-guided Standard or Dose-escalated Tumour Boost Radiotherapy (RAIDER).
    Clin Oncol (R Coll Radiol). 2021 Mar 22. pii: S0936-6555(21)00055.
    PubMed    


  174. SHKOLYAR E, Zhao Q, Mach KE, Teslovich NC, et al
    Bladder cancer risk stratification using a urinary mRNA biomarker panel - A path towards cystoscopy triaging.
    Urol Oncol. 2021 Mar 22. pii: S1078-1439(21)00072.
    PubMed    
    Abstract available

  175. KHAKI AR, Shan Y, Nelson RE, Kaul S, et al
    Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer.
    Urol Oncol. 2021 Mar 22. pii: S1078-1439(21)00114.
    PubMed    
    Abstract available

  176. BASILE G, Pederzoli F, Bandini M, Raggi D, et al
    Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand?
    Urol Oncol. 2021 Mar 22. pii: S1078-1439(21)00081.
    PubMed    
    Abstract available

  177. SMRKOLJ T, Cegovnik Primozic U, Fabjan T, Sterpin S, et al
    The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors.
    Radiol Oncol. 2020 Dec 29. pii: raon-2020-0072. doi: 10.2478/raon-2020-0072.
    PubMed    
    Abstract available

  178. ZUPANCIC D, Romih R
    Immunohistochemistry as a paramount tool in research of normal urothelium, bladder cancer and bladder pain syndrome.
    Eur J Histochem. 2021;65.
    PubMed    
    Abstract available

  179. IBILIBOR C, Psutka SP, Herrera J, Rivero JR, et al
    The association between sarcopenia and bladder cancer-specific mortality and all-cause mortality after radical cystectomy: A systematic review and meta-analysis.
    Arab J Urol. 2021;19:98-103.
    PubMed    
    Abstract available

  180. ARORA A, Pugliesi F, Zugail AS, Moschini M, et al
    Higher nodal yield with robot-assisted pelvic lymph node dissection for bladder cancer compared to laparoscopic dissection: implications for more accurate staging.
    Arab J Urol. 2020;19:92-97.
    PubMed    
    Abstract available

  181. CHIANCONE F, Fabiano M, Carrino M, Fedelini M, et al
    Impact of systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) in patients with non-muscle-invasive bladder cancer after bacillus Calmette-Guerin failure.
    Arab J Urol. 2021;19:86-91.
    PubMed    
    Abstract available

  182. NOWAK L, Krajewski W, Moschini M, Chorbinska J, et al
    Assessment of the oncological outcomes of three different bacillus Calmette-Guerin strains in patients with high-grade T1 non-muscle-invasive bladder cancer.
    Arab J Urol. 2021;19:78-85.
    PubMed    
    Abstract available

  183. CARANDO R, Soldini E, Cotrufo S, Zazzara M, et al
    Electro-mediated drug administration of mitomycin C in preventing non-muscle-invasive bladder cancer recurrence and progression after transurethral resection of the bladder tumour in intermediate- and high-risk patients.
    Arab J Urol. 2020;19:71-77.
    PubMed    
    Abstract available

  184. NOWAK L, Krajewski W, Poterek A, Sliwa A, et al
    The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette-Guerin immunotherapy: Current status.
    Arab J Urol. 2020;19:67-70.
    PubMed    
    Abstract available

  185. VOLZ Y, Eismann L, Pfitzinger PL, Jokisch JF, et al
    Prognostic impact of perioperative blood transfusions on oncological outcomes of patients with bladder cancer undergoing radical cystectomy: A systematic review.
    Arab J Urol. 2020;19:24-30.
    PubMed    
    Abstract available

  186. ORNAGHI PI, Afferi L, Antonelli A, Cerruto MA, et al
    Frailty impact on postoperative complications and early mortality rates in patients undergoing radical cystectomy for bladder cancer: a systematic review.
    Arab J Urol. 2020;19:9-23.
    PubMed    
    Abstract available

  187. MARI A, Muto G, Di Maida F, Tellini R, et al
    Oncological impact of inflammatory biomarkers in elderly patients treated with radical cystectomy for urothelial bladder cancer.
    Arab J Urol. 2020;19:2-8.
    PubMed    
    Abstract available

  188. LIN A, Qiu Z, Zhang J, Luo P, et al
    Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer.
    Front Immunol. 2021;12:630773.
    PubMed    
    Abstract available

  189. LAUKHTINA E, Abufaraj M, Al-Ani A, Ali MR, et al
    Intravesical Therapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence.
    Eur Urol Focus. 2021 Mar 21. pii: S2405-4569(21)00095.
    PubMed    
    Abstract available

  190. LODHI T, Song YP, West C, Hoskin P, et al
    Hypoxia and its Modification in Bladder Cancer: Current and Future Perspectives.
    Clin Oncol (R Coll Radiol). 2021 Mar 21. pii: S0936-6555(21)00092.
    PubMed    
    Abstract available

  191. CHOI SJ, Park KJ, Heo C, Park BW, et al
    Radiomics-based model for predicting pathological complete response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
    Clin Radiol. 2021 Mar 21. pii: S0009-9260(21)00151.
    PubMed    
    Abstract available

  192. YANG J, Liu X, Dai G, Qu L, et al
    CircNT5E promotes the proliferation and migration of bladder cancer via sponging miR-502-5p.
    J Cancer. 2021;12:2430-2439.
    PubMed    
    Abstract available

  193. FENG F, Chen AP, Wang XL, Wu GL, et al
    Circ_0061140 promotes metastasis of bladder cancer through adsorbing microRNA-1236.
    Eur Rev Med Pharmacol Sci. 2021;25:2157.
    PubMed    
    Abstract available

  194. MAFFEZZINI M, Fontana V, Pacchetti A, Dotta F, et al
    Age above 70 years and Charlson Comorbidity Index higher than 3 are associated with reduced survival probabilities after radical cystectomy for bladder cancer. Data from a contemporary series of 334 consecutive patients.
    Arch Ital Urol Androl. 2021;93:15-20.
    PubMed    
    Abstract available

  195. TRIGO S, Gonzalez K, Di Matteo L, Ismail A, et al
    Bacillus Calmette-Guerin vaccine and bladder cancer incidence: Scoping literature review and preliminary analysis.
    Arch Ital Urol Androl. 2021;93:1-8.
    PubMed    
    Abstract available

  196. ZHANG X, Liu G, Shi X, Shi X, et al
    Sequential administration of anti-PD-1 and anti-Tim-3 combined with an SA-GM-CSF-anchored vaccine overcomes adaptive immune resistance to reject established bladder cancer.
    J Cancer. 2021;12:2000-2009.
    PubMed    
    Abstract available

  197. ZHOU JQ, Kang XL, Xu CJ, Liu S, et al
    Construction of Decision Trees Based on Gene Expression Omnibus Data to Classify Bladder Cancer and Its Subtypes.
    Med Sci Monit. 2021;27:e929394.
    PubMed    
    Abstract available

  198. LOYAL A, Chopra S, Goel M, Mehta S, et al
    Predictors of toxicity after neoadjuvant chemoradiotherapy for locally advanced gall bladder cancer.
    Indian J Cancer. 2021 Jan 27. pii: 308058. doi: 10.4103.
    PubMed    
    Abstract available

  199. LI HZ, Zheng RS, Du LB, Zhang SW, et al
    [Bladder cancer incidence, mortality and temporal trends in China].
    Zhonghua Zhong Liu Za Zhi. 2021;43:293-298.
    PubMed    
    Abstract available

  200. ALMEIDA TC, Silva GND
    Resveratrol effects in bladder cancer: A mini review.
    Genet Mol Biol. 2021;44:e20200371.
    PubMed    
    Abstract available

  201. LIU Y, Wu Y, Zhang P, Xu C, et al
    CXCL12 and CD3E as Indicators for Tumor Microenvironment Modulation in Bladder Cancer and Their Correlations With Immune Infiltration and Molecular Subtypes.
    Front Oncol. 2021;11:636870.
    PubMed    
    Abstract available

  202. DU Y, Wang B, Jiang X, Cao J, et al
    Identification and Validation of a Stromal EMT Related LncRNA Signature as a Potential Marker to Predict Bladder Cancer Outcome.
    Front Oncol. 2021;11:620674.
    PubMed    
    Abstract available

  203. DENG Y, Hong X, Yu C, Li H, et al
    Preclinical analysis of novel prognostic transcription factors and immune-related gene signatures for bladder cancer via TCGA-based bioinformatic analysis.
    Oncol Lett. 2021;21:344.
    PubMed    
    Abstract available

  204. D'ELIA C, Folchini DM, Mian C, Hanspeter E, et al
    Diagnostic value of Xpert((R)) Bladder Cancer Monitor in the follow-up of patients affected by non-muscle invasive bladder cancer: an update.
    Ther Adv Urol. 2021;13:1756287221997183.
    PubMed    
    Abstract available

  205. MOHSENZADEGAN M, Bavandpour P, Nowroozi MR, Amini E, et al
    The Potential of T Cell Immunoglobulin and Mucin-Domain containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer.
    Endocr Metab Immune Disord Drug Targets. 2021 Mar 10. pii: EMIDDT-EPUB-114830.
    PubMed    
    Abstract available

  206. PAN S, Li S, Xiao M, Chen D, et al
    Significant benefit of everolimus in a patient with urothelial bladder cancer harboring a rare M1043I mutation of PIK3CA.
    Invest New Drugs. 2021 Mar 20. pii: 10.1007/s10637-021-01103.
    PubMed    
    Abstract available

  207. ROMER E, Esperto F, Dooldeniya M, Cumberbatch MG, et al
    Does minimally invasive surgery for bladder cancer result in unusual sites of metastasis?
    Actas Urol Esp. 2021 Mar 17. pii: S0210-4806(20)30257.
    PubMed    
    Abstract available

  208. BUERGER M, Kapahnke S, Omran S, Schomaker M, et al
    Aortic aneurysm and aortic graft infection related to Mycobacterium bovis after intravesical Bacille Calmette-Guerin therapy-a case series.
    BMC Surg. 2021;21:138.
    PubMed    
    Abstract available

  209. MISHRA SJ, Liu W, Beebe K, Banerjee M, et al
    The Development of Hsp90beta-Selective Inhibitors to Overcome Detriments Associated with pan-Hsp90 Inhibition.
    J Med Chem. 2021;64:1545-1557.
    PubMed    
    Abstract available

  210. KRISHAN A, Bruce A, Khashaba S, Abouelela M, et al
    Safety and Efficacy of Transurethral Resection of Bladder Tumor Comparing Spinal Anesthesia with Spinal Anesthesia with an Obturator Nerve Block: A Systematic Review and Meta-analysis.
    J Endourol. 2021;35:249-258.
    PubMed    
    Abstract available

  211. PANIAGUA M, Parra V, De Miguel E
    Urinary bladder lipoma: an illustrative case.
    J Radiol Case Rep. 2020;14:15-21.
    PubMed    
    Abstract available

  212. LI J, Huang S, Zhang Y, Zhuo W, et al
    LINC00460 Enhances Bladder Carcinoma Cell Proliferation and Migration by Modulating miR-612/FOXK1 Axis.
    Pharmacology. 2021;106.
    PubMed    
    Abstract available

  213. LAI S, Wu P, Diao T, Seery S, et al
    Does Xylinas' nomogram accurately predict intravesical recurrence risk after radical nephroureterectomy for primary upper urinary tract urothelial carcinoma when applied to Asian populations?
    Jpn J Clin Oncol. 2021;51:469-477.
    PubMed    
    Abstract available

  214. BADA M, De Concilio B, Crocetto F, Creta M, et al
    Laparoscopic radical cystectomy with extracorporeal urinary diversion: an Italian single-center experience with 10-year outcomes.
    Minerva Urol Nefrol. 2020;72:641-643.
    PubMed    


  215. DESOUKY E
    BCG versus COVID-19: impact on urology.
    World J Urol. 2021;39:823-827.
    PubMed    
    Abstract available

  216. ZHANG H, Shan G, Song J, Tian Y, et al
    Extracellular matrix-related genes play an important role in the progression of NMIBC to MIBC: a bioinformatics analysis study.
    Biosci Rep. 2020;40.
    PubMed    
    Abstract available

  217. OVIEDO RAMIREZ MI, Garzon Arana A
    Nephrogenic adenoma of the bladder. A simulator of urothelial bladder neoplasia.
    Actas Urol Esp. 2020;44:258-259.
    PubMed    


  218. DEL POZO JIMENEZ G, Herranz Amo F, Subira Rios D, Rodriguez Fernandez E, et al
    Mortality prediction model for patients with bladder urothelial tumor after radical cystectomy.
    Actas Urol Esp. 2020;44:215-223.
    PubMed    
    Abstract available

  219. EISSA A, Zoeir A, Ciarlariello S, Sarchi L, et al
    En-bloc resection of bladder tumors for pathological staging: the value of lateral margins analysis.
    Minerva Urol Nefrol. 2020;72:763-769.
    PubMed    
    Abstract available

  220. ABRAHAMSSON J, Kollberg P, Almquist H, Blackberg M, et al
    Complete Metabolic Response with FDG-PET-CT Predicts Survival after Induction Chemotherapy in patients with Clinically Node-positive Bladder Cancer.
    BJU Int. 2021 Feb 24. doi: 10.1111/bju.15374.
    PubMed    
    Abstract available

  221. FICARRA V, Crestani A, Rossanese M, Alario G, et al
    Retrosigmoid ileal conduit without transposition of the left ureter after open radical cystectomy for bladder cancer.
    BJU Int. 2021 Mar 10. doi: 10.1111/bju.15375.
    PubMed    
    Abstract available

  222. REZENDE LFM, Lee DH, Keum N, Wu K, et al
    Resistance training and total and site-specific cancer risk: a prospective cohort study of 33,787 US men.
    Br J Cancer. 2020;123:666-672.
    PubMed    
    Abstract available

  223. SOTTNIK JL, Vanderlinden LA, Joshi M, Chauca-Diaz A, et al
    Androgen Receptor Regulates CD44 Expression in Bladder Cancer.
    Cancer Res. 2021 Mar 9. pii: 0008-5472.CAN-20-3095.
    PubMed    
    Abstract available

  224. PACKIAM VT, Richards J, Schmautz M, Heidenreich A, et al
    The current landscape of salvage therapies for patients with bacillus Calmette-Guerin unresponsive nonmuscle invasive bladder cancer.
    Curr Opin Urol. 2021;31:178-187.
    PubMed    
    Abstract available

  225. GROENEVELD CS, Fontugne J, Cabel L, Bernard-Pierrot I, et al
    Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
    Eur J Cancer. 2021;148:181-189.
    PubMed    
    Abstract available

  226. ABU-SALHA Y, Smith AB
    Seeing the Unseen: Uncovering Patient-reported Outcomes in Bladder Cancer.
    Eur Urol. 2021 Feb 23. pii: S0302-2838(21)00143.
    PubMed    


  227. GRABBERT M, Seiler R, Gratzke C
    Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial Boorjian SA, Alemozaffar M, Konety BR, et al Lancet Oncol 2021;22:107-17.
    Eur Urol. 2021 Feb 20. pii: S0302-2838(21)00099.
    PubMed    


  228. BRYAN RT, Liu W, Pirrie SJ, Amir R, et al
    Comparing an Imaging-guided Pathway with the Standard Pathway for Staging Muscle-invasive Bladder Cancer: Preliminary Data from the BladderPath Study.
    Eur Urol. 2021 Feb 27. pii: S0302-2838(21)00141.
    PubMed    
    Abstract available

  229. ROSIELLO G, Piazza P, Tames V, Farinha R, et al
    The Impact of Previous Prostate Surgery on Surgical Outcomes for Patients Treated with Robot-assisted Radical Cystectomy for Bladder Cancer.
    Eur Urol. 2021 Feb 27. pii: S0302-2838(21)00149.
    PubMed    
    Abstract available

  230. KHAN MS, Omar K, Ahmed K, Gan C, et al
    Long-term Oncological Outcomes from an Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL).
    Eur Urol. 2020;77:110-118.
    PubMed    
    Abstract available

  231. MOSCHINI M, Shariat SF, Black P, Kamat AM, et al
    Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails.
    Eur Urol. 2020;77:1-2.
    PubMed    
    Abstract available

  232. VETTERLEIN MW, Klemm J, Gild P, Bradtke M, et al
    Improving Estimates of Perioperative Morbidity After Radical Cystectomy Using the European Association of Urology Quality Criteria for Standardized Reporting and Introducing the Comprehensive Complication Index.
    Eur Urol. 2020;77:55-65.
    PubMed    
    Abstract available

  233. TREVISANI F, Di Marco F, Raggi D, Bettiga A, et al
    Renal function outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab and radical cystectomy in the pure-01 study.
    Int J Cancer. 2021 Mar 15. doi: 10.1002/ijc.33554.
    PubMed    
    Abstract available

  234. KUBOTA M, Kanno T, Inoue T, Yamasaki T, et al
    Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: A matched-pair analysis in a multicenter cohort.
    Int J Urol. 2021 Mar 7. doi: 10.1111/iju.14533.
    PubMed    
    Abstract available

  235. HERR H
    Does asymptomatic bacteriuria affect the response to intravesical bacillus Calmette-Guerin?
    Int J Urol. 2020;27:72-74.
    PubMed    
    Abstract available

  236. HAYAKAWA N, Kikuchi E
    Editorial Comment to Effect of optimal neoadjuvant chemotherapy on oncological outcomes of locally advanced bladder cancer with laparoscopic radical cystectomy: A matched-pair analysis in a multicenter cohort.
    Int J Urol. 2021 Mar 18. doi: 10.1111/iju.14557.
    PubMed    


  237. MIYAMOTO T, Miyake M, Toyoshima Y, Fujii T, et al
    Clinical outcomes after intravesical bacillus Calmette-Guerin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019.
    Int J Urol. 2021 Mar 18. doi: 10.1111/iju.14545.
    PubMed    
    Abstract available

  238. TULLY KH, Reese SW, Cole AP, Noldus J, et al
    Temporal trends in the incidence of distant-stage bladder cancer among young individuals.
    Int J Urol. 2021 Mar 14. doi: 10.1111/iju.14550.
    PubMed    


  239. HUANG H, Yan B, Hao H, Shang M, et al
    Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis.
    Int J Urol. 2021 Mar 13. doi: 10.1111/iju.14537.
    PubMed    
    Abstract available

  240. KANNO T
    Editorial Comment from Dr Kanno to Laparoscopic versus open radical cystectomy in 607 patients with bladder cancer: Comparative survival analysis.
    Int J Urol. 2021 Mar 13. doi: 10.1111/iju.14551.
    PubMed    


  241. FUKUSHIMA H
    Editorial Comment from Dr Fukushima to Temporal trends in the incidence of distant-stage bladder cancer among young individuals.
    Int J Urol. 2021 Mar 26. doi: 10.1111/iju.14558.
    PubMed    


  242. TAOKA R, Tsunemori H, Matsuoka Y, Kohashiguchi K, et al
    Use of surgical checklist during transurethral resection increases detrusor muscle collection rate and improves recurrence-free survival in patients with non-muscle-invasive bladder cancer.
    Int J Urol. 2021 Mar 19. doi: 10.1111/iju.14548.
    PubMed    
    Abstract available

  243. WU YT, Luo HL, Wang HJ, Chen YT, et al
    Gender effect on the oncologic outcomes of upper urinary tract urothelial carcinoma in Taiwan.
    Int Urol Nephrol. 2020;52:1043-1048.
    PubMed    
    Abstract available

  244. BHAT A, Kwon D, Soodana-Prakash N, Mouzannar A, et al
    Surveillance Intensity in Intermediate Risk Nonmuscle Invasive Bladder Cancer: Revisiting the Optimal Timing and Frequency of Cystoscopy.
    J Urol. 2021 Feb 22:101097JU0000000000001689. doi: 10.1097/JU.0000000000001689.
    PubMed    
    Abstract available

  245. ZHU D, Srivastava A, Agalliu I, Fram E, et al
    Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population.
    J Urol. 2021 Feb 22:101097JU0000000000001694. doi: 10.1097/JU.0000000000001694.
    PubMed    
    Abstract available

  246. DONAT SM, Tan KS, Jibara G, Dalbagni G, et al
    Intraoperative Ureteral Stent Use at Radical Cystectomy is Associated with Higher 30-Day Complication Rates.
    J Urol. 2021;205:483-490.
    PubMed    
    Abstract available

  247. CACCIAMANI GE, Medina L, Lin-Brande M, Tafuri A, et al
    Timing, Patterns and Predictors of 90-Day Readmission Rate after Robotic Radical Cystectomy.
    J Urol. 2021;205:491-499.
    PubMed    
    Abstract available

  248. ELSAYED AS, Gibson S, Jing Z, Wijburg C, et al
    Rates and Patterns of Recurrences and Survival Outcomes after Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium.
    J Urol. 2021;205:407-413.
    PubMed    
    Abstract available

  249. GALLIOLI A, Territo A, Mercade A, Fontana M, et al
    The Impact of Ureteroscopy following Computerized Tomography Urography in the Management of Upper Tract Urothelial Carcinoma.
    J Urol. 2021;205:392-399.
    PubMed    
    Abstract available

  250. WEI XX, Werner L, Teo MY, Rosenberg JE, et al
    Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma.
    J Urol. 2021;205:414-419.
    PubMed    
    Abstract available

  251. CHESNUT GT, Tin AL, Sjoberg DD, Jang B, et al
    Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy.
    J Urol. 2021;205:400-406.
    PubMed    
    Abstract available

  252. BAUSCH K, Halbeisen FS, Aghlmandi S, Sutter SU, et al
    Reply by Authors.
    J Urol. 2021;205:998.
    PubMed    


  253. ZHENG R, Du M, Ge Y, Gao F, et al
    Identification of low-frequency variants of UGT1A3 associated with bladder cancer risk by next-generation sequencing.
    Oncogene. 2021 Mar 3. pii: 10.1038/s41388-021-01672.
    PubMed    
    Abstract available

  254. JIA M, Su B, Mo L, Qiu W, et al
    Circadian clock protein CRY1 prevents paclitaxelinduced senescence of bladder cancer cells by promoting p53 degradation.
    Oncol Rep. 2021;45:1033-1043.
    PubMed    
    Abstract available

  255. CHOU KY, Chang AC, Tsai TF, Lin YC, et al
    MicroRNA34a5p serves as a tumor suppressor by regulating the cell motility of bladder cancer cells through matrix metalloproteinase2 silencing.
    Oncol Rep. 2021;45:911-920.
    PubMed    
    Abstract available

  256. CHEN X, Chen S
    LINC00649 promotes bladder cancer malignant progression by regulating the miR15a5p/HMGA1 axis.
    Oncol Rep. 2021;45:1.
    PubMed    
    Abstract available

  257. GONDRAN-TELLIER B, Abdallah R, Sichez PC, Akiki A, et al
    Continuous saline bladder irrigation after blue light transurethral resection of bladder tumor increases recurrence-free survival in low- to intermediate-risk non-muscle invasive bladder cancer.
    Prog Urol. 2021 Mar 1. pii: S1166-7087(21)00028.
    PubMed    
    Abstract available

  258. YANG X, Zhuang J, Yu H, Cao Q, et al
    Effect of Coronavirus Disease 2019 on Patients with Bladder Cancer in China.
    Urol Int. 2021 Feb 24:1-3. doi: 10.1159/000512895.
    PubMed    


  259. MIYAKE M, Iida K, Nishimura N, Miyamoto T, et al
    Non-maintenance intravesical Bacillus Calmette-Guerin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.
    BMC Cancer. 2021;21:266.
    PubMed    
    Abstract available

  260. CHEN F, Wang Q, Zhou Y
    The construction and validation of an RNA binding protein-related prognostic model for bladder cancer.
    BMC Cancer. 2021;21:244.
    PubMed    
    Abstract available

  261. UYSAL D, Kowalewski KF, Kriegmair MC, Wirtz R, et al
    A comprehensive molecular characterization of the 8q22.2 region reveals the prognostic relevance of OSR2 mRNA in muscle invasive bladder cancer.
    PLoS One. 2021;16:e0248342.
    PubMed    
    Abstract available

  262. WANG K, Yang JC, Jang YJ, Chen GY, et al
    19-(Benzyloxy)-19-oxojolkinolide B (19-BJB), an ent-abietane diterpene diepoxide, inhibits the growth of bladder cancer T24 cells through DNA damage.
    PLoS One. 2021;16:e0248468.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;